LaBrosse Nicole — SEC Form 4 filings
SEC reporting owner CIK 1910662. 15 Form 4 filings on record with FilingPulse; latest filed 2026-02-24.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-02-13 to 2026-02-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 9 legs across 4 filings — 57,227 shares, $3,515,453 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 66.
- Largest priced transaction: sale of 13,240 shares @ $75.93 ($1,005,300) in HALOZYME THERAPEUTICS, INC., filed 2025-09-11.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | 15 | — | 9 legs · 57,227 sh · $3,515,453 | 66 |
Form 4 filings — LaBrosse Nicole
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-02-24 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Option exercise (M): 5,332 @ $0 · Tax withholding (F): 2,876 @ $70.98 · Option exercise (M): 6,688 @ $0 · Tax withholding (F): 3,608 @ $70.64 · Option exercise (M): 5,332 (derivative) @ $0 · Option exercise (M): 6,688 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Option exercise (M): 5,093 @ $0 · Tax withholding (F): 2,747 @ $79.44 · Option exercise (M): 5,329 @ $0 · Tax withholding (F): 2,874 @ $79.44 · Option exercise (M): 13,351 @ $0 · Tax withholding (F): 7,273 @ $79.44 · +3 more | EDGAR |
| 2026-02-11 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 5,167 (derivative) @ $0 · Grant/award (A): 7,448 (derivative) @ $0 · Grant/award (A): 29,502 (derivative) @ $0 | EDGAR |
| 2025-09-23 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Sale (S): 1,913 @ $77.83 · Sale (S): 314 @ $78.67 | EDGAR |
| 2025-09-11 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Option exercise (M): 11,271 @ $12.07 · Option exercise (M): 1,135 @ $12.49 · Sale (S): 6,760 @ $75.29 · Sale (S): 13,240 @ $75.93 · Option exercise (M): 11,271 (derivative) @ $0 · Option exercise (M): 1,135 (derivative) @ $0 | EDGAR |
| 2025-02-24 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Option exercise (M): 6,688 @ $0 · Tax withholding (F): 3,601 @ $57.75 · Option exercise (M): 6,688 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 22,603 (derivative) @ $0 · Grant/award (A): 21,327 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Option exercise (M): 1,254 @ $0 · Tax withholding (F): 741 @ $58.29 · Option exercise (M): 17,409 @ $0 · Tax withholding (F): 9,400 @ $58.29 · Option exercise (M): 5,093 @ $0 · Tax withholding (F): 2,742 @ $58.29 · +6 more | EDGAR |
| 2025-02-14 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 6,050 (derivative) @ $0 · Grant/award (A): 5,221 (derivative) @ $0 · Grant/award (A): 6,935 (derivative) @ $0 · Grant/award (A): 28,662 (derivative) @ $0 | EDGAR |
| 2024-07-23 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Option exercise (M): 4,008 @ $22.50 · Sale (S): 4,008 @ $53.85 · Option exercise (M): 992 @ $22.50 · Sale (S): 992 @ $54.25 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Option exercise (M): 10,000 @ $22.50 · Sale (S): 10,000 @ $51.82 · Option exercise (M): 10,000 @ $22.50 · Sale (S): 10,000 @ $51.93 · Option exercise (M): 10,000 @ $22.50 · Sale (S): 10,000 @ $52.04 · +3 more | EDGAR |
| 2024-02-27 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 27,722 (derivative) @ $0 · Grant/award (A): 26,751 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Option exercise (M): 5,093 @ $0 · Tax withholding (F): 2,737 @ $36.10 · Option exercise (M): 5,329 @ $0 · Tax withholding (F): 2,864 @ $36.10 · Option exercise (M): 5,093 (derivative) @ $0 · Option exercise (M): 5,329 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Option exercise (M): 1,254 @ $0 · Tax withholding (F): 686 @ $35.91 · Option exercise (M): 1,254 (derivative) @ $0 | EDGAR |
| 2024-02-13 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Option exercise (M): 2,502 @ $0 · Tax withholding (F): 1,477 @ $35.49 · Option exercise (M): 2,502 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1910662 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →